{
    "id": 25679,
    "fullName": "MYCN positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MYCN positive indicates the presence of the MYCN gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4613,
        "geneSymbol": "MYCN",
        "terms": [
            "MYCN",
            "bHLHe37",
            "MODED",
            "N-myc",
            "NMYC",
            "ODED"
        ]
    },
    "variant": "positive",
    "createDate": "10/27/2016",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19871,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCi975 treatment inhibited viability of a Mycn-positive neuroblastoma cell line in culture (PMID: 31679823).",
            "molecularProfile": {
                "id": 26697,
                "profileName": "MYCN positive"
            },
            "therapy": {
                "id": 9235,
                "therapyName": "MYCi975",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17557,
                    "pubMedId": 31679823,
                    "title": "Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31679823"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9035,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroendocrine prostate cancer cell line, positive for AKT1, AURKA, and MYCN, demonstrated decreased MYCN expression and reduced cell viability in culture, and decreased tumor volume in xenograft models when treated with CD532 (PMID: 27050099).",
            "molecularProfile": {
                "id": 26699,
                "profileName": "AKT1 pos AURKA pos MYCN pos"
            },
            "therapy": {
                "id": 1628,
                "therapyName": "CD532",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6885,
                    "pubMedId": 27050099,
                    "title": "N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27050099"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9036,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Alisertib (MLN8237) in culture did not result in decreased expression of MYCN and led to minimal effects on cell viability in a neuroendocrine prostate cancer cell line positive for AKT1, AURKA, and MYCN (PMID: 27050099).",
            "molecularProfile": {
                "id": 26699,
                "profileName": "AKT1 pos AURKA pos MYCN pos"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6885,
                    "pubMedId": 27050099,
                    "title": "N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27050099"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26697,
            "profileName": "MYCN positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26699,
            "profileName": "AKT1 pos AURKA pos MYCN pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}